Trinity Biotech PLC
NASDAQ:TRIB
Trinity Biotech PLC
Research & Development
Trinity Biotech PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Trinity Biotech PLC
NASDAQ:TRIB
|
Research & Development
-$4.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Medtronic PLC
NYSE:MDT
|
Research & Development
-$2.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
STERIS plc
NYSE:STE
|
Research & Development
-$111.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Trinity Biotech PLC
Glance View
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.
See Also
What is Trinity Biotech PLC's Research & Development?
Research & Development
-4.2m
USD
Based on the financial report for Jun 30, 2025, Trinity Biotech PLC's Research & Development amounts to -4.2m USD.
What is Trinity Biotech PLC's Research & Development growth rate?
Research & Development CAGR 10Y
0%
Over the last year, the Research & Development growth was 3%. The average annual Research & Development growth rates for Trinity Biotech PLC have been -2% over the past three years , 4% over the past five years .
